NASDAQ · BGNE
Healthcare · Biotechnology
$184.71
Up+$0.90 (+0.49%)
Updated Aug 13, 2026, 9:47 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BGNE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BGNE.
BGNE research
Company profile and research snapshot.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 25, 2025
Zymeworks, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference, Leerink Global Healthcare Conference, Barclays 27th Annual Global Healthcare Conference, and Jefferies Biotech on the Beach Summit.
Benzinga · Sep 25, 2024
The FDA is reviewing the use of PD-1 cancer drugs from Merck and Bristol Myers Squibb for gastric cancer treatment. Data shows these drugs may only benefit patients with high PD-L1 expression, while those with low expression see little advantage and face potential risks.
Benzinga · Sep 18, 2024
JMP Securities initiated coverage on BeiGene, a Chinese biotech firm, noting it as a 'unique investment opportunity'. The analyst is confident in the company's lead cancer drug, Brukinsa, which is expected to capture a significant market share in the BTK inhibitor market.
Investing.com · Jul 4, 2024
BeiGene CFO Wang Julia Aijun sold 472 American Depositary Shares worth over $67,000 as part of a mandatory tax withholding provision related to the vesting of a restricted share unit award. The sale indicates the CFO's confidence in the company's prospects.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BGNE.
No results
No recent SID articles mention BGNE.
